Presenting today are RxSight President and Chief Executive Officer, Dr. Ron Kurtz; and Chief Financial Officer, Shelley Thunen. Yesterday evening, RxSight released preliminary revenue results for the ...

Yesterday evening, RxSight released preliminary revenue results ... delay procedures indefinitely by continuing to wear their glasses or contact lenses. However, a softening of the overall premium ...

RxSight, Inc. (NASDAQ:RXST – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports.

RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism ...

RxSight lowered 2025 revenue outlook to $160 million-$175 million, below the $188.9 million estimate. BofA downgrades RxSight to Underperform, citing slowing growth. Price target cut from $36 to $ ...

RxSight (NASDAQ:RXST), a maker of light-adjustable intraocular lenses, fell ~28% in the premarket on Thursday after the company slashed its full-year guidance and announced lower-than-expected ...

RxSight Inc. reported its Q1 2025 financial results, showing a 28% year-over-year increase in revenue to $37.9 million, despite a 6% sequential decline. The company revised its full-year revenue ...

RxSight Inc. reported its Q1 2025 financial results, showing a 28% year-over-year increase in revenue to $37.9 million, despite a 6% sequential decline. The company revised its full-year revenue ...

ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients ...

(RTTNews) - RxSight Inc. (RXST) expects preliminary first quarter 2025 revenue to be approximately $37.9 million, representing growth of 28% compared to the prior year period. Analysts expect the ...